CRS + HIPEC provides significant benefits to HCC-PM patients, with 89.0% 1-year and 3-year OS rates. Some patients achieved prolonged PFS, enhancing treatment options for this challenging condition. Incorporating CRS + HIPEC into the treatment regimen is a strategic therapeutic choice for HCC-PM patients, supported by the study’s findings of extended survival outcomes.
Journal Article by Yan G, Zhang K, Yan L and Zhang Y in World J Surg Oncol
© 2024. The Author(s).